Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)

On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It accrued its terms nonsubjective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. The company’s Alpha-1 Antitrypsin Deficiency programme received a favorable regulatory update earlier the change. The latest regulatory enactment was Bernstein’s main banal catalyst for 2026. The institution besides noted respective impending benchmarks, specified arsenic the anticipated merchandise of revised AATD information successful the archetypal 4th of 2026, which are inactive important events to support an oculus connected done the extremity of the year.

Separately, UBS began covering Beam Therapeutics Inc. (NASDAQ:BEAM) connected January 7, 2026, with a $28 terms extremity and a neutral rating. The motorboat was a constituent of a larger sum enactment that targeted 22 small- to mid-cap biotechnology firms. As reported by UBS, biotechnology fundamentals are starting to amended aft a challenging time, and capitalist assurance is expected to rebound, mounting the manufacture up for further occurrence successful 2026.

Beam Therapeutics Inc. (NASDAQ:BEAM) is simply a biotechnology steadfast focused connected processing a caller people of precision familial drugs.

While we admit the imaginable of BEAM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 20 Best Performing Stocks successful 2025 and 12 Best Food Stocks to Buy successful 2026. 

Disclosure: None. This nonfiction is primitively published at Insider Monkey.